Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis

References

• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 8;365(23):2205–2219. doi:10.1056/NEJMra1004965.
   PubMed Web of Science ®Google Scholar
• Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis. Am J Manag Care. 2014 May;20(7 Suppl):S128–S135.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol. 2005 Dec;32(12):2410–2415.
   PubMed Web of Science ®Google Scholar
• Gabriel SE. Why do people with rheumatoid arthritis still die prematurely? Ann Rheum Dis. 2008 Dec;67(Suppl 3):iii30–4. doi:10.1136/ard.2008.098038.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016 Jan;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985 Mar;312(13):818–822.
   PubMed Web of Science ®Google Scholar
• Kievit W, Fransen J, de Waal Malefijt MC, et al. Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. Rheumatology (Oxford). 2013 Aug;52(8):1500–1508.
   PubMed Web of Science ®Google Scholar
• Pincus T, Gibson KA, Castrejón I. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013;71 Suppl 1:S9–S19.
   PubMedGoogle Scholar
• Pincus T. RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013;71(2):117–120.
   PubMedGoogle Scholar
• Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1604–1611.
   PubMed Web of Science ®Google Scholar
• Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum. 2012 Sep;64(9):2824–2835.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Martin Mola E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis. 2014 Sep;73(9):1595–1597. doi:10.1136/annrheumdis-2013-205002.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004 Sep;63(9):1062–1068.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006 Sep;54(9):2817–2829.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar;73(3):492–509.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2016. MAbs. 2016 Feb-Mar;8(2):197–204. doi:10.1080/19420862.2015.1125583.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2015. MAbs. 2015;7(1):1–8. doi:10.4161/19420862.2015.988944.
   PubMed Web of Science ®Google Scholar
• Drugs@ FDA: FDA Approved Drug Products. [ cited 2016 Apr 8]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
   Google Scholar
• Shahouri SH, Michaud K, Mikuls TR, et al. Remission of rheumatoid arthritis in clinical practice: application of the American college of rheumatology/European league against rheumatism 2011 remission criteria. Arthritis Rheum. 2011 Nov;63(11):3204–3215.
   PubMed Web of Science ®Google Scholar
• Rafique A, Martin J, Blome M, et al. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor alpha. Ann Rheum Dis. 2013;72(Suppl 3):A797.
   Google Scholar
• Taylor PC, Moore A, Vasilescu R, et al. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016 May;36(5):685–695.
   PubMed Web of Science ®Google Scholar
• Gleason PP, Alexander GC, Starner CI, et al. Health plan utilization and costs of specialty drugs within 4 chronic conditions. J Manag Care Pharm. 2013 Sep;19(7):542–548.
   PubMed Web of Science ®Google Scholar
• O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013 Jul 25;369(4):307–318.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012 May;379(9827):1712–1720.
   PubMed Web of Science ®Google Scholar
• Sparks JA, Krumme AA, Shrank WH, et al. Brief report: intensification to triple therapy after treatment with nonbiologic disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States from 2009 to 2014. Arthritis Rheumatol. 2016 Feb;68:1588–1595. doi:10.1002/art.v68.7.
   PubMedGoogle Scholar
• Hopson S, Saverno K, Liu LZ, et al. Impact of out-of-pocket costs on prescription fills among new initiators of biologic therapies for rheumatoid arthritis. J Manag Care Spec Pharm. 2016 Feb;22(2):122–130.
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013 May;381(9877):1541–1550.
   PubMed Web of Science ®Google Scholar
• Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014 Jan;73(1):86–94.
   PubMed Web of Science ®Google Scholar
• Porter D, van Melckebeke J, Dale J, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016 May;388:239–247. doi:10.1016/S0140-6736(16)00380-9.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008 Nov;67(11):1516–1523.
   PubMed Web of Science ®Google Scholar
• Vander Cruyssen B, Van Looy S, Wyns B, et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther. 2006;8(4):R112.
   PubMedGoogle Scholar
• Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005 Nov;5(12):1731–1740.
   PubMed Web of Science ®Google Scholar
• Tocilizumab Full Prescribing Information. 2016 [cited 2016 Apr 14]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125276lbl.pdf
   Google Scholar
• Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011 Mar;63(3):609–621.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008 Mar;371(9617):987–997.
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010 Jan;69(1):88–96.
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008 Oct;58(10):2968–2980.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008 Nov;112(10):3959–3964.
   PubMed Web of Science ®Google Scholar
• Kim GW, Lee NR, Pi RH, et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res. 2015;38(5):575–584.
   PubMed Web of Science ®Google Scholar
• Boulanger MJ, Chow DC, Brevnova EE, et al. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 2003 Jun;300(5628):2101–2104. doi:10.1126/science.1083901.
   PubMed Web of Science ®Google Scholar
• Radin AR, Mellis SJ, Jasson M, et al. REGN88/SAR153191, A fully-human interleukin-6 receptor monoclonal antibody, reduces acute phase reactants in patients with rheumatoid arthritis: preliminary observations from phase 1 studies. Arthritis Rheum: Blackwell. 2010;62(Suppl 10):1121.
   Google Scholar
• Belomestnov P, Hamilton J, DiCioccio AT, et al. Sarilumab, a subcutaneously-administered, fully human monoclonal antibody inhibitor of the IL-6 receptor: pharmacokinetic profile and its relationship to changes in pharmacodynamic markers in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(Suppl 10):S576.
   Google Scholar
• Huizinga TWJ, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014 Sep;73(9):1626–1634.
   PubMed Web of Science ®Google Scholar
• Thiolat A, Semerano L, Pers YM, et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol. 2014 Feb;66(2):273–283.
   PubMed Web of Science ®Google Scholar
• Roll P, Muhammad K, Schumann M, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011 May;63(5):1255–1264.
   PubMed Web of Science ®Google Scholar
• Scott CT. Mice with a human touch. Nat Biotechnol. 2007 Oct;25(10):1075–1077. doi:10.1038/nbt1007-1075.
   PubMed Web of Science ®Google Scholar
• Rothstein B, Gottlieb A. Secukinumab for treating plaque psoriasis. Expert Opin Biol Ther. 2016 Jan;16(1):119–128. doi:10.1517/14712598.2016.1121986.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015 Jun;67(6):1424–1437.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727–735.
   PubMed Web of Science ®Google Scholar
• Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum. 2002 Apr;46(4):913–920.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Castelar-Pinheiro G, Brzezicki J, et al. Efficacy and safety of sarilumab in combination with csdmards in patients with active rheumatoid arthritis who were indadequate responders or intolerant of anti-TNF therapy: results from a phase 3 study [abstract]. Arthritis Rheumatol. 2015;67(suppl 10):A970.
   Web of Science ®Google Scholar
• Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015 Jun;74(6):1051–1057.
   PubMed Web of Science ®Google Scholar
• Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924–2937.
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhang X, Xiao L, et al. Comparative effectiveness of biologic therapy regimens for ankylosing spondylitis: a systematic review and a network meta-analysis. Medicine (Baltimore). 2016 Mar;95(11):e3060. doi:10.1097/MD.0000000000003060.
   PubMedGoogle Scholar
• Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov. 2007 Jan;6(1):75–92. doi:10.1038/nrd2196.
   PubMed Web of Science ®Google Scholar
• Emery P, Rondon J, Garg A, et al. Safety and tolerability of subcutaneous sarilumab compared to intravenous tocilizumab in patients with A. Arthritis Rheum. 2015;67(Suppl 10):Abstract 971.
   Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Furst D, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 Sep;73(9):1607–1615.
   PubMed Web of Science ®Google Scholar